Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm
Authors:
- Elena CrisàECElena Crisà
- Irene DogliottiIDIrene Dogliotti
- Giuseppe LiaGLGiuseppe Lia
- Marco CerranoMCMarco Cerrano
- Ernesta AudisioEAErnesta Audisio
- Giuseppe LanzaroneGLGiuseppe Lanzarone
- Lucia BrunelloLBLucia Brunello
- Daniela CaravelliDCDaniela Caravelli
- Fabrizio Carnevale SchiancaFSFabrizio Carnevale Schianca
- Enrico BerrinoEBEnrico Berrino
- Sara Erika BellomoSBSara Erika Bellomo
- Alice BartoliniABAlice Bartolini
Open Access
Abstract
Background/Objectives. Recent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML). Methods. This prospective study assessed gene mutation dynamics via next-generation sequencing (NGS) in 84 MDS/AML patients treated with intensive chemotherapy or hypomethylating agents plus venetoclax. Results. At diagnosis, 95% had somatic mutations detected by NGS, while only 29% had a measurable residual disease (MRD) marker with qPCRs. NGS at complete remission (CR) was performed in 56/71 patients who achieved CR; 59% had persisting mutations, mostly in DNMT3A, TET2, and ASXL1 (DTA mutations). Mutations’ persistence in CR was linked to a shorter relapse-free survival (RFS; median 8 months vs. not reached, HR 4.41, 95% CI 1.69–11.49; p = 0.002) and overall survival (OS; 2-year OS: 51.5% vs. 88%, HR 4.02, 95% CI 1.39–11.65; p = 0.001). Combining NGS and multiparameter flow cytometry (MFC) for MRD detection, we divided patients into three groups with distinct RFS (NGS−/MFC−, NGS−/MFC+, or NGS+/MFC− and NGS+/MFC+), with double-negative patients displaying the best RFS (p < 0.001). In the multivariate analysis, NGS and MFC MRD+ were independent predictors of RFS. Conclusions. This real-world study confirms the added prognostic role of NGS in MRD detection on RFS, particularly when combined with MFC. This approach may improve risk stratification and guide treatment decisions.Keywords
Funding Information
- FPRC 5 × 1000 Ministero della Salute 2021 EMAGEN—FaBer
- Italian Ministry of Health, Ricerca Corrente 2025
- Janssen Pharmaceutical Companies of Johnson & Johnson
This publication has 59 references indexed in Scilit:
- DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantJAMA, 2023
- Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialThe Lancet Haematology, 2022
- Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsAmerican Journal of Hematology, 2022
- Single cell analysis of clonal architecture in acute myeloid leukaemiaLeukemia, 2018
- Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaLeukemia, 2018
- Methods of Detection of Measurable Residual Disease in AMLCurrent Hematologic Malignancy Reports, 2017
- Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationTransplantation and Cellular Therapy, 2017
- DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaLeukemia, 2017
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid LeukemiaJAMA, 2015
- Myelodysplastic syndromesThe Lancet, 2014